Ventures

Respiosa offers a groundbreaking solution for obstructive sleep apnea (OSA), a condition affecting millions worldwide. Unlike traditional treatments like CPAP or surgery, Respiosa provides a minimally invasive, surgically implanted solution specifically targeting tongue-based obstruction, a common cause of OSA. Developed by Philips, Respiosa promises effective, durable, and adjustable therapy with a quick recovery time. With its natural and unobtrusive design, Respiosa ensures high patient adherence, addressing a significant gap in OSA treatment options.

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

AiSentia addresses the challenge of using contrast dye in CT scans. They've developeda patient-centric solution that eliminates the need for contrast agents and reduces associated risks like patient discomfort, allergic reactions, and radiation exposure. Their technology uses AI to get more information from regular CT scans, making them safer for checking arteries. Since approximately 2% of the population suffers from conditions such as contrast-induced nephropathy or kidney failure, AiSentia's technology makes CTA scans more accessible while seamlessly integrating into existing clinical workflows.

DiaphOne Therapeutics is developing treatments for diabetic complications and neurodegenerative diseases. The company develops first-in-class small molecule RAGE antagonists that target the intracellular RAGE-DIAPH1 pathway, showing improved efficacy over extracellular approaches. Backed by NLC Health Ventures, DiaphOne Therapeutics leverages cutting-edge research from NYU Langone Health and The University at Albany, SUNY and has demonstrated promising proof of concept preclinical results. Currently advancing lead optimisation studies, DiaphOne is bringing forward curative therapies for diabetic complications and neurodegeneration, with the support of NLC’s Health Impact Fund for its preclinical development.

Arne enhances urgent neonatal care by using augmented reality and artificial intelligence to provide real-time clinical decision support. In stressful situations, doctors can miss critical protocol steps, but Arne’s smart software projects recommends actions directly into the doctor's field of vision, reducing errors and improving patient outcomes. This innovative tool ensures every newborn receives optimal care, while empowering neonatologists.

The rising number of surgeries in healthcare systems like the National Health Service is challenging due to increasing demand and backlogs. However, new solutions like the Asclepius Platform aim to streamline assessments before and after surgery using digital tools and AI. By analyzing patient data, it helps doctors make better decisions, reduce complications, and improve patient outcomes. Designed with input from patients, it's a cost-effective way to make surgery safer and more efficient.

ArtiFex tackles a solution for coronary and peripheral bypass surgeries. Traditional grafts from the great saphenous vein face issues like rapid degeneration, leading to complications. With millions of bypass surgeries conducted annually and a billion-dollar market for vascular grafts, there's a clear need for improvement. ArtiFex's innovative vascular graft, made of cobalt-chrome and cellulose promotes tissue regeneration, strength, and ensures blood flow without causing clotting or immune reactions.

Innofuse is revolutionizing care for the most fragile among us: preterm infants in Neonatal Intensive Care Units (NICUs). Their innovative Tulive® IV-set ensures these tiny patients receive medication with precision and immediacy, sparing them from the risks of inaccurate or delayed drug administration. By reducing fluctuations and eliminating overshoot, Tulive® safeguards against potential brain damage, offering hope and reassurance to families in NICUs worldwide.